experimental treatments


    Can Preclinical Data Guide Clinical Cancer Therapy?

    With: Keith Flaherty, MD

    A Q&A with Keith Flaherty, MD, Associate Professor of Medicine, Harvard Medical School; Director of Developmental Therapeutics, Cancer Center, Massachusetts General Hospital; kflaherty@mgh.harvard.edu Originally published Aug 31, 2016 Q: Under what circumstances and to what extent are you willing to take clinical actions on a cancer patient based primarily on preclinical data? A: There are two scenarios that come to mind when thinking about… Read more »

  •   Emma Shtivelman, PhD


    “When approved therapies don’t work, or stop working, for people with serious or life-threatening illnesses, it puts them in a difficult position. Some turn to clinical trials that are testing experimental treatments. But many can’t do that because they are too sick, don’t meet the requirements of the trial, or can’t afford to travel to the site of a trial. That doesn’t mean they are out of options.”

    Go to full article published by STAT on Aug 2, 2017.

    If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.